AstraZeneca seeks U.S. approval

AstraZeneca said Thursday that it intends to seek full regulatory approval from the U.S. Food and Drug Administration for its COVID19 vaccine in the second half of this year, further delaying the longawaited application. The AngloSwedish drugmaker said the company and its partners have delivered more than 1 billion doses of the vaccine to over 170 countries where it is already authorized.